Nothing Special   »   [go: up one dir, main page]

Koh et al., 2024 - Google Patents

VGF and VGF-derived peptide AQEE30 stimulate osteoblastic bone formation through C3a receptor

Koh et al., 2024

View PDF
Document ID
11994417339514900464
Author
Koh J
Moon S
Kim J
Lee Y
Cho H
Choi Y
Yoon J
Kim D
Che X
Jin X
Baek I
Lee S
Choi J
Publication year

External Links

Snippet

New therapeutic targets, especially those that stimulate bone formation in cortical bone, are needed to overcome the limitations of current anti-osteoporotic drugs. We previously demonstrated that factors secreted from megakaryocytes (MK) promote bone formation. In …
Continue reading at www.researchsquare.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Han et al. Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts
Wang et al. Wnt and the Wnt signaling pathway in bone development and disease
Suen et al. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review
Baron et al. WNT signaling in bone homeostasis and disease: from human mutations to treatments
Lerner et al. The WNT system: background and its role in bone
Ansari et al. Autocrine and paracrine regulation of the murine skeleton by osteocyte‐derived parathyroid hormone‐related protein
DK2711023T3 (en) osteogenesis
Furuya et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity
Boudin et al. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases
US7541431B2 (en) Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
Valdés et al. IGF‐1 induces IP3‐dependent calcium signal involved in the regulation of myostatin gene expression mediated by NFAT during myoblast differentiation
Villa et al. CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway
Xing et al. Targeted disruption of leucine‐rich repeat kinase 1 but not leucine‐rich repeat kinase 2 in mice causes severe osteopetrosis
EP2165716B1 (en) Novel bone mass increasing agent
Kanazawa Adiponectin in metabolic bone disease
Morello et al. Brachy–syndactyly caused by loss of Sfrp2 function
JP2010532360A (en) Modulator of AXL for use in the treatment of bone disorders
Arvigo et al. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines
Ohsawa et al. The inhibitory core of the myostatin prodomain: its interaction with both type I and II membrane receptors, and potential to treat muscle atrophy
EP2976094B1 (en) Methods of treating metabolic disorders
Jin et al. Intranasal delivery of RGD motif-containing osteopontin icosamer confers neuroprotection in the postischemic brain via α v β 3 integrin binding
Um et al. Bone morphogenic protein 9 is a novel thermogenic hepatokine secreted in response to cold exposure
Koh et al. VGF and VGF-derived peptide AQEE30 stimulate osteoblastic bone formation through C3a receptor
WO2008066744A9 (en) Methods and compositions for treating and preventing spinal cord injury and other neuronal disease or injury
Kim et al. Stanniocalcin 1 and 1, 25-dihydroxyvitamin D3 cooperatively regulate local bone mineralization by osteoblasts